We found a cure for cancer genetic

New drug may be hope for thousands of women with hereditary breast cancer or ovarian cancer. The study found that the drug significantly reduces the size of tumors in patients in the final stages of the disease.

Scientists from King's College London found that a novel targeted medicine olaparib   attacking cancer cells, the formation of which was caused by genetic factors. These "cancer genes" cause only one UK 1 500 cases breast cancer And every tenth case Ovarian Cancer .

These studies are published in the prestigious scientific journal The Lancet. They show that about 40% of patients with breast cancer and 30% of patients with ovarian cancer after a course of therapy olaparibom   There is a reduction of tumors. Moreover, their development has been stopped for at least six months.

All participants of the study prior to initiating therapy olaparibom   We pass through a standard treatment in the form of chemotherapy, which have no apparent clinical effects. In all patients was recorded the final stage of cancer Deemed terminal. This makes the opening of British scientists is especially significant, as is currently the medicine can not offer any effective drugs for the final stages of cancer Breast and   ovary .

Yet olaparib   passes through the stage of clinical trials, the drug is not released into general availability. Experts believe this facility one of the most promising targeted agents currently being developed by science.

Industry News

Go back to the main page